New hope for rare, aggressive stomach cancer: drug combo aims to make tumors operable
NCT ID NCT07515625
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs (sintilimab, bevacizumab, and chemotherapy) in people with a rare and aggressive type of stomach cancer that produces a protein called AFP. The goal is to shrink the tumors enough so they can be surgically removed. About 46 adults with advanced stomach cancer that has not spread too far will receive the treatment, and researchers will measure how many respond and can have successful surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AFP GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can an AI coach and simple exercises help cancer patients fight frailty?
- Electric acupoint therapy may speed digestion and ease pain after stomach cancer surgery
- New imaging tracer could spot hidden cancers and fibrosis in one scan
- New PET tracer aims to spot hidden cancer spread in the abdomen
- Triple attack on stomach cancer: radiation, chemo, and a smart antibody